0001193125-22-144423.txt : 20220509 0001193125-22-144423.hdr.sgml : 20220509 20220509084104 ACCESSION NUMBER: 0001193125-22-144423 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220503 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220509 DATE AS OF CHANGE: 20220509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GoodRx Holdings, Inc. CENTRAL INDEX KEY: 0001809519 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374] IRS NUMBER: 475104396 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39549 FILM NUMBER: 22903402 BUSINESS ADDRESS: STREET 1: 2701 OLYMPIC BOULEVARD CITY: SANTA MONICA STATE: CA ZIP: 90404 BUSINESS PHONE: (855) 268-2822 MAIL ADDRESS: STREET 1: 2701 OLYMPIC BOULEVARD CITY: SANTA MONICA STATE: CA ZIP: 90404 8-K 1 d338017d8k.htm 8-K 8-K
false 0001809519 0001809519 2022-05-03 2022-05-03





Washington, D.C. 20549









Date of report (Date of earliest event reported): May 3, 2022



GoodRx Holdings, Inc.

(Exact Name of Registrant as Specified in its Charter)




Delaware   001-39549   47-5104396

(State or Other Jurisdiction

of Incorporation)



File Number)


(IRS Employer

Identification No.)

2701 Olympic Boulevard

Santa Monica, CA 90404

(Address of Principal Executive Offices) (Zip Code)

(855) 268-2822

(Registrant’s telephone number, including area code)


(Former Name or Former Address, if Changed Since Last Report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities registered pursuant to Section 12(b) of the Act:


Title of each class





Name of each exchange

on which registered

Class A Common Stock, $0.0001 par value per share   GDRX   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Item 5.02

Departure of Directors of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 3, 2022, GoodRx Holdings, Inc. (the “Company”) determined that Andrew Slutsky, President, Consumer, and a named executive officer of the Company, would transition to a new role as Senior Vice President, Strategy and Marketing Innovation with the Company in a non-executive officer capacity, which will be effective as of May 9, 2022. As of such date, Mr. Slutsky will continue his employment with the Company reporting directly to its Co-Chief Executive Officers focusing on new initiatives.

On May 9, 2022, the Company also announced the appointment of Raj Beri as Chief Operating Officer, effective May 23, 2022.

Mr. Beri, 48, served as VP of Global Grocery and New Verticals at Uber Technologies, Inc. (“Uber”) from March 2020 to May 2022. Mr. Beri’s team oversaw non-restaurant delivery businesses for Uber globally. Previously between February 2018 and February 2020, he led the Uber Eats business in Asia Pacific, Europe, Middle East and Africa. Prior to joining the Uber Eats team, Mr. Beri served as a Business Head for Uber India from June 2016 to January 2018. While at Uber, Mr. Beri also served on the Board of Comershop, now a fully owned Uber subsidiary. Before joining Uber in 2016, Raj served as Chief Operating Officer for Adadyn, an IDG Ventures backed based Ad-Tech company with operations in San Francisco, New York City and Bangalore. Mr. Beri has also served as Director and Chief Operating Officer of lgoUgo, a Travelocity business unit and as VP, Travel at Oversee.net. Additionally, he was Director of Digital for the McGraw-Hi/I Company and worked in the Digital Strategy practice at Monitor Group. Mr. Beri has an M.B.A. from the Wharton School at the University of Pennsylvania, a M.S. in Aerospace Engineering from Arizona State University and a B.S. in Aerospace Engineering from the University of Toronto.

In connection with his appointment as Chief Operating Officer, Mr. Beri entered into an offer letter with the Company (the “Offer Letter”) providing for: (1) an annual base salary of $500,000; (2) an annual discretionary performance bonus of up to 100% of his annual base salary, prorated for his first year of employment and subject to his continued employment through the bonus payment date; (3) a one-time signing bonus in the amount of $500,000, which is subject to repayment upon his voluntary resignation during his first year of employment; (4) eligibility for a retention bonus in the amount of $500,000, which is subject to forfeiture upon his provision of notice of resignation or termination for cause (as defined in the Offer Letter) during his first year of employment; (5) eligibility to participate in the employee benefits and benefit plans generally available to employees; (6) a restricted stock unit award covering shares of the Company’s Class A Common Stock with a value of $10.8 million, which vests in equal quarterly installments over a four-year period, subject to continued employment; (7) a nonqualified stock option to purchase shares of the Company’s Class A Common Stock with a value of $7.2 million, based on the grant date Black-Sholes fair value, which vests in equal quarterly installments over a four-year period, subject to continued employment; and (8) at-will employment. Pursuant to the Offer Letter, Mr. Beri may not sell or otherwise transfer any shares issued to him pursuant to the restricted stock unit award and/or the stock option prior to the one-year anniversary of his employment start date.

Upon Mr. Beri’s termination of employment without cause, then, subject to his timely execution and non-revocation of a release of claims, he will be eligible to receive (i) a lump sum payment equal to 12 months of his then-current base salary; (ii) a lump sum payment equal to 100% of his target annual performance bonus for the year in which the termination occurs; and (iii) four months of Company-paid COBRA continuation coverage premiums. If Mr. Beri’s employment is terminated without cause within 24 months following a change in control (as defined in the Company’s 2020 Incentive Award Plan), then, subject to his timely execution and non-revocation of a release of claims, he will be eligible to receive (i) a lump sum payment equal to 12 months of his then-current base salary; (ii) a lump sum payment equal to 100% of his target annual performance bonus for the year in which the termination occurs; (iii) six months of Company-paid COBRA continuation coverage premiums; and (iv) full accelerated vesting of the restricted stock unit award and stock option award granted under the Offer Letter.

The foregoing description of the Offer Letter does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Offer Letter, a copy of which is filed as Exhibit 10.1 hereto and is incorporated by reference herein.

Item 9.01

Financial Statements and Exhibits

(d)    Exhibits


Exhibit No.



10.1    Offer Letter for Raj Beri, dated May 6, 2022.
104    Cover Page Interactive Data File, formatted in inline XBRL.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



/s/ Karsten Voermann

Name:   Karsten Voermann
Title:   Chief Financial Officer

Date: May 9, 2022

EX-10.1 2 d338017dex101.htm EX-10.1 EX-10.1

Exhibit 10.1



Date: May 6th, 2022

Name: Raj Beri

Email: rajberi@gmail.com



GoodRx, Inc. Offer of Employment

Dear Raj,

On behalf of GoodRx, Inc., a Delaware corporation (the “Company” or “GoodRx”), we are pleased to offer you full-time employment in the position of Chief Operating Officer, subject to the following terms and conditions (“Offer Letter”).

Start Date and Location

Your employment start date will be May 23rd, 2022 (“Start Date”). Your primary employment location will be New York, but you agree that fulfilling your job responsibilities will require frequent travel to the Company’s headquarters in Santa Monica, California.

Base Salary

As a full-time exempt employee, you will initially earn a base salary of $41,666.67 monthly ($500,000 annualized), paid twice monthly on the Company’s normal payroll schedule, subject to regular withholdings. Your base salary will be subject to review annually as part of the Company’s normal salary review process, and any salary adjustment will be made solely in the Company’s discretion based on individual and Company performance.

Annual Performance Bonus

In addition to the base salary, you will be eligible for an annual discretionary performance bonus of up to 100% of your annual base salary (“Incentive Bonus”), prorated for your first year of employment based on your start date. To be eligible for the Incentive Bonus, you must be continuously employed by the Company through the end of the calendar year covered by the Incentive Bonus and remain employed by the Company at the time of the payment. The Incentive Bonus earned for each fiscal year (if any) shall be paid as soon as practicable following the Company’s Board of Directors (the “Board”) approval of the amount of the Incentive Bonus, subject to the conditions set forth in this paragraph. The final decision on the amount of the Incentive Bonus that will be paid (if any) shall be determined by GoodRx in its sole discretion.

Sign-On Bonus

The Company will also provide you with an advance of a one-time signing bonus in the amount of $500,000, subject to all regular payroll taxes (“Signing Bonus”). This Signing Bonus will be advanced to you in one lump sum in a separate check on the next regularly scheduled pay date after you start employment with GoodRx. This Signing Bonus advance is taxable, and all regular payroll taxes will be withheld. Should you voluntarily resign from GoodRx at any time prior to your one-year anniversary date with the Company (i.e., one year from your Start Date), the Signing Bonus will not be earned, and the advance of the bonus must be paid back to the Company in full within 3 months of the date of your resignation. For the avoidance of doubt, should your employment terminate for any other reason, including without Cause (defined below), prior to your one-year anniversary date with the Company, you will not be required to repay this Signing Bonus advance.

Retention Bonus

Upon completion of one year of service for the Company, you will be eligible for a $500,000 retention bonus, less all applicable withholdings and deductions required by law (“Retention Bonus”), subject to the following conditions: To earn the bonus, you must be continuously employed by the Company from your Start Date until the one-year anniversary of your Start Date (“Retention Period”). If you have given notice of your intent to resign from employment on or before the last day of the Retention Period, the Retention Bonus shall have been forfeited in its entirety. If you have been involuntarily terminated by the Company for Cause (as defined below) during the Retention Period, the Retention Bonus shall have been forfeited in its entirety.


You shall be eligible to participate in all the employee benefits and benefit plans that the Company generally makes available to its full-time regular employees, subject to the terms and conditions of such benefits and benefit plans. Detailed information about the benefits presently available will be provided to you upon your employment. You will be eligible for vacation pursuant to the Company’s Flexible Vacation policy. You will also receive separate paid sick leave in accordance with the Company’s sick leave policy.


The Board has approved granting you a restricted stock unit award covering $10.8 million in share value of shares of class A Common Stock of GoodRx Holdings, Inc. under the applicable incentive plan (the “Plan”), calculated based on the average closing share price over the last 20 trading days preceding the date on which the board approves the grant (“RSU Award”). Your award will vest over time as you provide services to the Company or GoodRx Holdings, Inc. Subject to your continuous employment with the Company, and subject to approval of the Board, these shares will vest as follows: RSUs will vest at a rate of 1/16th of the total shares vesting on a quarterly basis over a four-year period, with the first 1/16th vesting during the month following your first full quarter of service after your Start Date. The exact date of vesting each quarter will be determined by the Board. The award will be evidenced by your RSU Agreement of GoodRx Holdings, Inc., and will be subject to the terms and conditions of the Plan.

Additionally, the Board has approved a non-statutory option grant to purchase $7.2 million shares of Common Stock of GoodRx Holdings, Inc. under the Plan (together with the RSU Award covering $10.8 million in share value as described in the preceding paragraph, the “Initial Award”).



The number of shares of options to be granted will be determined based on the grant date Black-Scholes fair value, and the exercise price of the option shares will be the fair market value (closing price) of the Common Stock of GoodRx Holdings, Inc. on the date on which the Board approves the grant. Subject to your continuous employment with the Company, and subject to approval of the Board, these option shares will vest as follows: Option shares will vest at a rate of 1/16th of the total shares on a quarterly basis over a four-year period, with the first 1/16th vesting during the month following your first full quarter of service after your Start Date. The exact date of vesting each quarter will be determined by the Board. The exercise price of the option shares will be the fair market value (closing price) of the Common Stock of GoodRx Holdings, Inc. on the date on which the Board approves the grant. The option shares will be evidenced by your Stock Option Agreement of GoodRx Holdings, Inc., and will be subject to the terms and conditions of the Plan.

You acknowledge and agree that the above Initial Award will be subject to a one-year post-vesting holding period, meaning you may not sell or otherwise transfer the shares issued pursuant to this Initial Award until your one-year anniversary with the Company as determined based upon your Start Date (defined above). The details of this post-vesting holding requirement will be set forth in your applicable RSU Agreement and Stock Option Agreement evidencing the awards. This holding requirement may be modified only by the Board and/or the Compensation Committee in their sole discretion.

You represent to the Company that you have reviewed with your own financial/tax advisors the tax consequences of this Initial Award and this Offer Letter, and that you are relying solely on such advisors and not on any statements or representations of the Company or any of its agents.

As part of the annual performance review process, you may be eligible for a discretionary equity award. The availability of and your eligibility for any such grants shall be based upon your performance, Company performance, current market conditions, and approval by the Board of Directors and Compensation Committee. The Board and Compensation Committee maintain sole discretion to approve any additional annual grants.

Severance and Change of Control

In the event the Company terminates your employment without Cause (defined below), and subject to your executing a release of claims against the Company, the Company shall pay you the following: (a) a lump sum payment equal to twelve (12) months of severance, paid at your annual base salary at the time of your termination of employment and subject to all applicable payroll deductions, and (b) a lump sum payment equal to your full target Incentive Bonus (defined above). These amounts shall be paid within 30 days following your execution of the release of claims.

In the event the Company terminates your employment due to a Change in Control (as defined in the Plan), the Board agrees that, notwithstanding the vesting schedule set forth in the “Equity” section above, the Initial Award (defined above) will fully vest, provided, however, that (a) your termination occurs within 24 months following that Change in Control and (b) your termination is not the result of a termination for Cause. The timing of such vesting pursuant to this paragraph will be determined by the Board but will occur no later than 60 days following your execution of a signed release of claims.



As used herein, “Cause” shall mean (i) a commission by you of a felony or other serious crime, or the commission of any act or omission involving fraud with respect to the Company or any of its affiliates or any of their respective customers, suppliers, vendors or other business relations; (ii) any conduct causing the Company or any of its subsidiaries public disgrace or disrepute or material economic harm, including but not limited to your reporting to work under the influence of alcohol or illegal drugs, or the use of illegal drugs (whether or not at the workplace); (iii) a material failure by you to perform your responsibilities or duties to the Company; (iv) your breach of fiduciary duty, gross negligence or willful misconduct with respect to the Company or any of its affiliates; or (v) the commission of any other act or omission by you involving dishonesty or disloyalty to the material detriment of the Company or any of its affiliates, or any other act or omission that brings the Company or any of its subsidiaries into public disrepute.

To the extent provided by the federal COBRA law or, if applicable, state insurance laws, and by the Company’s current group health insurance policies, the Company shall pay for you to continue your group health insurance benefits during the relevant severance period (i.e., four months for involuntary termination without cause, or six months for termination due to Change in Control).

As indicated, the foregoing severance and Change of Control provisions shall be conditioned on timely execution of GoodRx’s standard release of employee claims.

Name & Likeness Rights

You hereby authorize the Company to use, reuse, and to grant others the right to use and reuse your name, photograph, likeness, voice, and biographical information, and any reproduction or simulation thereof, in any media now known or hereafter developed (including but not limited to film, video, and digital, or other electronic media), both during and after your employment, for whatever purposes the Company deems necessary.

No Expectation of Privacy

You recognize and agree that you have no expectation of privacy with respect to the Company’s telecommunications, networking or information processing systems (including, without limitation, stored computer files, email messages and voice messages) and that your activity, and any files or messages, on or using any of those systems may be monitored at any time without notice.

“At Will” Employment

Employment with the Company is “at-will.” This means that it is not for any specified period of time and can be terminated either by you or by the Company at any time, with or without advance notice, and for any or no particular reason or cause. It also means that your job duties, title, responsibilities, reporting level, compensation and benefits, as well as the Company’s personnel policies and procedures, may be changed with or without notice at any time in the sole discretion of the Company. This letter will reflect the final, total and complete agreement between you and the Company regarding how your employment may be terminated. The “at-will” nature of your employment may only be changed by way of written agreement expressly altering the at-will employment relationship and signed by you and by the Company’s President.



Taxes and Code Section 409A

The Company may withhold from any amounts payable under this Letter such federal, state and local taxes as may be required to be withheld pursuant to any applicable law or regulation. We intend that any compensation, benefits, and other amounts payable or provided to you under this Letter first be exempt from the requirements of Section 409A of the Internal Revenue Code and all regulations, guidance, and other interpretative authority issued thereunder (collectively, “Section 409A”), to the maximum permissible extent, including as short-term deferrals pursuant to Treasury Regulation Section 1.409A-1(b)(4), and will be interpreted and construed consistently with such intent. To the extent that any payments under this Letter are not exempt from the requirements of Section 409A, then all such payments are intended to be paid or provided in compliance with Section 409A such that there will be no adverse tax consequences, interest, or penalties for you under Section 409A as a result of the payments and benefits so paid or provided to you.

Reporting and Loyalty

You will initially report to the Company’s Co-CEO. Your report may be changed from time to time by the Company.

You agree to the best of your ability and experience that you will loyally and conscientiously perform all of the duties and obligations required of you. During your employment, you will devote substantially all of your business time and attention to the business of the Company, the Company will be entitled to all of the benefits and profits arising from or incident to all such work services and advice, you will not provide general consulting or advisor services in the healthcare or any related industry, whether or not for compensation, without the prior written consent of the Company, and you will not directly or indirectly engage or participate in any business that is competitive in any manner with the business of the Company. You also agree that you will not engage in any outside activity or industry event as an expert, speaker, contributor, consultant, advisor, or panelist that would create an actual or potential conflict with your duties for the Company or may result in you divulging the Company’s nonpublic or confidential information. If you would like to participate in any such external activity, you will get prior written consent from the Company and ensure the proposed activity does not present an actual or potential conflict and will not involve disclosure of the Company’s confidential information. During your employment you may not use or disclose the Company’s confidential information except as required to perform your duties. As set forth below, your employment is contingent upon your compliance with the terms of the Company’s Proprietary Information and Invention Assignment Agreement during and after your employment. Nothing in this letter will prevent you from accepting speaking or presentation engagements in exchange for honoraria or from serving on boards of charitable organizations, or from owning no more than 1% of the outstanding equity securities of a corporation whose stock is listed on a national stock exchange.



By signing and accepting this offer, you represent and warrant that: (i) you are not subject to any pre-existing contractual or other legal obligation with any person, company or business enterprise which may be an impediment to your employment with, or your providing services to, the Company as its employee or officer; and (ii) you have not and shall not bring onto Company premises, or use in the course of your employment with the Company, any confidential or proprietary information of another person, company or business enterprise to whom you previously provided services.


This offer, and any employment pursuant to this offer, is conditioned upon the following:



Your ability to provide satisfactory documentary proof of your identity and right to work in the United States of America on or before your third day of employment.



Satisfactory outcome of pre-employment reference check.



Satisfactory outcome of post-offer background check.



Your signed agreement to, and ongoing compliance with, the terms of the Company’s Proprietary Information and Invention Assignment Agreement.

Your execution and return of the enclosed copy of this letter to Chief People Officer, Vina Leite no later than 5:00 pm Pacific Time, May 7th 2022, after which time this offer will expire.

Entire Agreement

If you accept this offer, and the conditions of this offer are satisfied, this letter and the written agreements referenced in this letter shall constitute the complete agreement between you and the Company with respect to the subject matter hereof. This letter agreement shall supersede any existing employment arrangement or agreement with the Company. Any representations, whether written or oral, not contained in this letter or contrary to those contained in this letter that may have been made to you are expressly cancelled and superseded by this offer. California law shall govern this agreement. If any provision of this letter agreement is held invalid or unenforceable, such provision shall be severed, and the remaining provisions shall continue to be valid and enforceable.







/s/ Trevor Bezdek

Trevor Bezdek, Co-CEO

I accept the above offer, and will begin employment on the date set forth below:


Signature:   /s/ Raj Beri
  Raj Beri
Date Signed:   5/6/2022
Start Date:   May 23, 2022



EX-101.SCH 3 gdrx-20220503.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 gdrx-20220503_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 gdrx-20220503_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g338017g35d19.jpg GRAPHIC begin 644 g338017g35d19.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
May 03, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001809519
Document Type 8-K
Document Period End Date May 03, 2022
Entity Registrant Name GoodRx Holdings, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39549
Entity Tax Identification Number 47-5104396
Entity Address, Address Line One 2701 Olympic Boulevard
Entity Address, City or Town Santa Monica
Entity Address, State or Province CA
Entity Address, Postal Zip Code 90404
City Area Code (855)
Local Phone Number 268-2822
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Class A Common Stock, $0.0001 par value per share
Trading Symbol GDRX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 d338017d8k_htm.xml IDEA: XBRL DOCUMENT 0001809519 2022-05-03 2022-05-03 false 0001809519 8-K 2022-05-03 GoodRx Holdings, Inc. DE 001-39549 47-5104396 2701 Olympic Boulevard Santa Monica CA 90404 (855) 268-2822 false false false false Class A Common Stock, $0.0001 par value per share GDRX NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://goodrx.com//20220503/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d338017d8k.htm d338017dex101.htm gdrx-20220503.xsd gdrx-20220503_lab.xml gdrx-20220503_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d338017d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d338017d8k.htm" ] }, "labelLink": { "local": [ "gdrx-20220503_lab.xml" ] }, "presentationLink": { "local": [ "gdrx-20220503_pre.xml" ] }, "schema": { "local": [ "gdrx-20220503.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gdrx", "nsuri": "http://goodrx.com/20220503", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d338017d8k.htm", "contextRef": "duration_2022-05-03_to_2022-05-03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://goodrx.com//20220503/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d338017d8k.htm", "contextRef": "duration_2022-05-03_to_2022-05-03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220503/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220503/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220503/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220503/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220503/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220503/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220503/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220503/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220503/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220503/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220503/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220503/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220503/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220503/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220503/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220503/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220503/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220503/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220503/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220503/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220503/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220503/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001193125-22-144423-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-144423-xbrl.zip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

_?P $0 @ &'%0 9#,S.# Q-V1E>#$P,2YH M=&U02P$"% ,4 " @1:E421C^XT(# ! "P $0 @ '+ M,P 9V1R>"TR,#(R,#4P,RYX"TR,#(R,#4P,U]L86(N>&UL4$L! M A0#% @ ($6I5.:YFN>Q! <"H !4 ( !R3T &=D I